Further studies of rimiterol and salbutamol administered by intermittent positive-pressure ventilation, and an important observation on the technique of using the Bennett ventilator.
1. Using the same technique of administering drugs by intermittent positive-pressure ventilation as used in previous studies a source of contamination of solutions nebulized was discovered. This was rectified by using a new ventilator and completely separate patient circuits for each solution nebulized. 2 Salbutamol 0.5% and 0.25% solutions achieved the same degree of bronchodilatation, but there was a significantly greater increase in heart rate produced by salbutamol 0.5%. 3 Rimiterol 0.5% and salbutamol 0.25% produced similar peak mean improvements in FEV and also induced the same degree of tachycardia, but the duration of these effects were significantly shorter in the case of rimiterol. 4 The sustained degree of bronchodilatation achieved by salbutamol 0.25% could not be mirrored by giving two doses of rimiterol 0.5%, the second dose 2 h after the first. 5 Rimiterol 0.5% induced a degree of tachycardia which was similar in peak effect to that observed after salbutamol 0.25%. However, in the controls the second dose of rimiterol, given 2 h after the first, was responsible for only a small increase in heart rate which was not significantly different than that after saline in the other three treatment groups.
D000328:Adult; D000368:Aged; D000420:Albuterol / Q000008:administration & dosage / Q000494:pharmacology*; D001249:Asthma / Q000503:physiopathology; D002396:Catechols / Q000494:pharmacology*; D005260:Female; D005541:Forced Expiratory Volume; D006339:Heart Rate; D006801:Humans; D007384:Intermittent Positive-Pressure Breathing / Q000295:instrumentation*; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D011175:Positive-Pressure Respiration / Q000295:instrumentation*; D013997:Time Factors
D002396:Catechols; D010880:Piperidines; C084590:rimiterol; D000420:Albuterol